Skip to main content
TipRanks
Go Ultimate75% OFF

AstraZeneca (AZN1N) Q3 2026 Earnings Report

0 Followers

MX:AZN1N Q3 2026 EPS Results

Actual EPS
MXN 51.89
Consensus EPS
MXN 48.10
Beat/Miss
Beat by +MXN 3.79
One Year Ago EPS
MXN 44.27

MX:AZN1N Q3 2026 Revenue Results

Actual Revenue
MXN 299.46B
Expected Revenue
MXN 297.65B
Beat/Miss
Beat by +MXN 1.80B
YoY Revenue Growth
+7.07%

Earnings Announcement Details

Quarter
Q3 2026
Date
10/30/2026
Time
TBA
Conference Call
Friday, October 30, 2026
MX:AZN1N Upcoming Earnings

AstraZeneca's next earnings date is estimated for February 11, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Oct 30, 2026|% Change Since:6.70%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. AstraZeneca reported solid revenue and EPS growth, broad-based commercial momentum, significant Phase III success, multiple new approvals and a deep pipeline with substantial 2027 catalysts. The company also reiterated full-year guidance and expressed confidence in growth through 2030 and beyond. Against this, the call included explicit challenges from loss of exclusivity, generic competition, VBP, lower operating cash flow, one clinical development discontinuation, higher investment and restructuring costs, and expected fourth-quarter expense pressures, but these were presented as manageable within the company's broader growth and pipeline strategy.

Company Guidance

For the full year, AstraZeneca continues to expect total revenue to increase by a mid- to high single-digit percentage and core EPS to increase by low double-digit percentage; core gross margins are expected to be stable to slightly higher than in 2025, R&D is expected to be at the upper end of the low 20s percentage range, and the core tax rate is expected to be within 18% to 22%. Full year CapEx is now expected to increase by low teens percentage compared to 2025, milestone payments relating to prior BD transactions are expected to be approximately $2.5 billion, other operating income in the second half is expected to be slightly higher than the first half, and operating expenses are expected to show a sequential step-up in the fourth quarter versus third quarter, with finance expenses also expected to be higher in the fourth quarter than in the third quarter. The Reshaping for Sustainable Growth program is expected to incur up to $2 billion in onetime restructuring costs and deliver $1.5 billion in annualized pretax run rate benefits, with activities expected to be completed by the end of 2029; for 2027, the company expects more than 20 high-value trial readouts and pivotal data for 9 potential new medicines, representing more than $20 billion in non-risk-adjusted peak year revenue.

  • Strong Year-to-Date Revenue and EPS GrowthFor the first 9 months of 2026, total revenue grew 7% and core EPS increased 14%. Excluding Farxiga and Brilinta, total revenue grew 12%, demonstrating the underlying strength of the broader portfolio.
  • Positive Pipeline Delivery and New Medicine ApprovalsAstraZeneca reported positive results from 12 Phase III programs since its full-year results in February and received first approvals for 4 new medicines, including Etcamah in the U.S. The company has now achieved 14 approved new molecular entities toward its goal of delivering 20 new medicines by 2030.
  • More Than $10 Billion of Potential from Positive Phase III ReadoutsThe 12 positive Phase III readouts represent more than $10 billion in non-risk-adjusted peak-year sales potential. Management said the positive data have removed much of the risk behind these opportunities and underpin confidence in the $80 billion 2030 ambition.
  • Broad Therapy-Area and Geographic GrowthOncology, rare disease and respiratory and immunology each delivered double-digit growth in the first 9 months. The U.S., Europe and emerging markets outside China also delivered robust growth.
  • Underlying China Growth Remained StrongChina growth continued to be affected by volume-based procurement, but excluding that impact, China grew 13% with growth across all therapy areas. Management also said underlying growth excluding the impact of VBP for Farxiga, roxadustat and Lynparza was at the level of the strong 15%.
  • Alliance Revenue Increased 32%Alliance revenue increased 32% in the first 9 months, driven by higher profit sales from partnered medicines Enhertu, Datroway and Tezspire in markets where partners record product sales.
  • Robust Gross Margin and Reaffirmed Full-Year GuidanceCore gross margin was 83% in the first 9 months. AstraZeneca continued to expect full-year core gross margin to be stable to slightly higher than in 2025, total revenue growth in the mid- to high single-digit percentage range and core EPS growth in the low double-digit percentage range.
  • Ongoing Investment in the Growth PipelineCore R&D expense increased 5% year-to-date and represented 23% of total revenue. The company is continuing to invest in bispecifics, cell therapies, T-cell engagers, weight management and cardiovascular outcome trials, with full-year R&D expected to be at the upper end of the low 20s percentage range.
  • Reshaping Program Targets Resource Redeployment and BenefitsAstraZeneca announced the 3-year Reshaping for Sustainable Growth program to redeploy resources and strengthen capabilities across existing businesses and therapy areas. It is expected to deliver $1.5 billion in annualized pretax run-rate benefits, with activities expected to be completed by the end of 2029.
  • Oncology Revenue Grew 16%Oncology total revenue grew 16% in the first 9 months to $21.9 billion, including 17% growth in the third quarter. Growth was double digit across all major regions, with U.S. growth of 18% and mid-teens growth in Europe and emerging markets.
  • Tagrisso Reached More Than $2 Billion in Quarterly RevenueTagrisso revenue was $2.1 billion in the third quarter, up 12% year over year and surpassing $2 billion for the first time. Demand was broad-based across indications and regions, while FLAURA2 maintained a leadership position in all major markets.
  • Strong Imfinzi and Imjudo Franchise GrowthImfinzi revenue grew 26% and Imjudo revenue grew 25% in the third quarter, with combined revenues exceeding $2 billion for the first time. Growth was broad-based across established indications and recent launches.
  • Calquence and Enhertu Continued to ExpandCalquence revenue increased 16% to $1.1 billion in the third quarter, and it became the leading BTK inhibitor in first-line CLL across the top 8 markets. Enhertu revenue grew 35% to $969 million, including nearly 50% growth in the U.S. and 40% growth in emerging markets.
  • Progress Across New Oncology LaunchesTruqap revenue grew 9% to $210 million. Datroway revenue reached $78 million, with uptake in late-line EGFR-mutated lung cancer and breast cancer. Etcamah showed encouraging early signals following its U.S. launch for SERENA-6, and Zegfrovy generated its first revenues in the third quarter before its U.S. launch for previously treated EGFR exon 20 insertion non-small cell lung cancer.
  • Positive Oncology Phase III DataSAFFRON reduced the risk of death by 32% versus platinum-based chemotherapy and extended median overall survival by nearly 5 months in selected patients after progression on Tagrisso. SANOVO extended median progression-free survival to more than 2 years versus just over 1 year with Tagrisso alone and showed a 9.6-month improvement in median overall survival.
  • Additional Breakthrough Oncology ReadoutsDESTINY-Lung04 produced median progression-free survival of 14.3 months and an objective response rate of 70% in HER2-mutant non-small cell lung cancer. DeLLphi-305 reduced the risk of death by 58% versus Imfinzi alone, with median overall survival of 21.1 months. VOLGA reduced the risk of recurrence, progression or death by 49% and the risk of death by 42%, while CLARITY-Gastric01 reduced the risk of death by 53% in third-line and later gastric cancer and doubled median overall survival from 5 to 10 months.
  • Deepening ADC and Immuno-Oncology PlatformsAstraZeneca entered an equity investment and clinical collaboration with Summit Therapeutics to combine ivonescimab with sone-ve and Datroway. The company has 15 Phase III trials for next-generation immuno-oncology bispecifics across 9 tumor types, including 6 trials combining bispecifics with ADCs.
  • Respiratory and Immunology GrowthR&I revenue increased 11% to $2.5 billion in the third quarter. Fasenra grew 14% to $602 million, Tezspire grew 51% to $429 million, Breztri grew 14% to $374 million and Saphnelo grew 32% to $235 million.
  • Tozorakimab Demonstrated Broad COPD EfficacyTozorakimab reduced COPD exacerbations by 23% in patients with baseline eosinophil counts below 150 cells per microliter, 34% in those with counts of 150 or higher and 43% in those with counts of 300 or higher. Reductions were up to 34% in former smokers and up to 30% in the overall population.
  • Tezspire Delivered Positive Eosinophilic Esophagitis DataIn the CROSSING trial, both Tezspire doses produced statistically significant and clinically meaningful improvements in histologic remission and the frequency and severity of difficulty swallowing at week 24, with improvements sustained through week 52. Approximately one-third of patients achieved total endoscopic remission.
  • Rare Disease Revenue Grew 11%Rare disease revenue grew 11% in the first 9 months to $7.5 billion, supported by double-digit growth across all key medicines. Ultomiris revenue increased 19% in the third quarter, Strensiq grew 34%, and Koselugo continued to deliver strong global momentum.
  • Rare Disease Launch Opportunities ExpandedUltomiris received accelerated U.S. approval in IgA nephropathy, Klygefa was approved in Japan for generalized myasthenia gravis, Amlypave was approved in Japan, and efzimfotase alfa was filed across major markets and received U.S. priority review with a PDUFA date expected in the first half of 2027.
  • Efzimfotase Alfa and Cliramitug Have Significant PotentialManagement said efzimfotase alfa could support broader patient reach than Strensiq through less frequent, lower-volume dosing, improved tolerability and broader disease coverage, with peak-year sales potential of $3 billion to $5 billion. Cliramitug is being evaluated on top of background therapy in ATTR cardiomyopathy and represents a stated $3 billion to $5 billion non-risk-adjusted peak revenue opportunity.
  • Weight Management and Cardiovascular Pipeline AdvancedPhase III trials are ongoing for elecoglipron, and the company initiated 3 Phase III trials for lenbelintide. AstraZeneca expects initial Phase III results for laroprovstat monotherapy in the first half of 2027 and results from the first 2 Phase III fixed-dose combination trials of laroprovstat and rosuvastatin in 2027.
  • Cell Therapy and T-Cell Engager Programs ProgressedAstraZeneca has 3 ongoing Phase III trials of AZD0120 in multiple myeloma and 2 Phase III trials of surovatamig in B-cell lymphomas. The company also has 4 additional clinical-stage cell therapies and 4 additional T-cell engagers in early development.
  • Large 2027 Pipeline Catalyst SetMore than 20 key Phase III readouts are planned for 2027, including pivotal data for 9 potential new medicines and more than $20 billion in non-risk-adjusted peak-year revenue potential. AstraZeneca also reported 12 programs with peak-year revenue potential above $5 billion and 4 programs with potential between $3 billion and $5 billion.
  • Balance Sheet Remained StrongCash flow from operating activities was $10.9 billion in the first 9 months. AstraZeneca said it remained comfortable with its current gross debt and reported a net debt-to-EBITDA ratio of 1.2x.
  • Strategic R&D Center OpenedAstraZeneca officially opened its new strategic R&D center in Kendall Square, Massachusetts, strengthening its presence in Greater Boston and placing scientists in a major life sciences ecosystem.

MX:AZN1N Earnings History

MX:AZN1N earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 11, 20272026 (Q4)43.08-39.43――
Oct 30, 20262026 (Q3)48.1051.8944.2717.23% (+7.63)
Jul 27, 20262026 (Q2)46.0548.9240.3621.20% (+8.56)
Apr 29, 20262026 (Q1)46.8547.9946.313.61% (+1.67)
Feb 10, 20262025 (Q4)38.8739.4338.871.44% (+0.56)
Nov 06, 20252025 (Q3)42.6544.2738.6914.42% (+5.58)
Jul 29, 20252025 (Q2)40.1840.3636.839.60% (+3.53)
Apr 29, 20252025 (Q1)41.9146.3138.3220.87% (+8.00)
Feb 06, 20252024 (Q4)38.5038.8726.9744.14% (+11.90)
Nov 12, 20242024 (Q3)38.0038.6932.1820.23% (+6.51)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed